A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Back to Search
Print
Bookmark Trial

NCT00417885

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Atlanta, Georgia, 30322, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- At least 18 years of age

- Estrogen and/or progesterone receptor positive adenocarcinoma of the breast with evidence of 1) unresectable 2)locally recurrent, or 3) metastatic disease

- Postmenopausal

- ECOG [Eastern Cooperative Oncology Group]

- Evaluable(e.g bone only disease allowed) and Measurable disease [RECIST (Response Evaluation Criterion in Solid Tumors)]

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- HER2 [Human Epidermal Growth factor Receptor 2] positive disease not previously
treated with herceptin


- Any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the
metastatic disease setting


- Radiation therapy within 2 weeks of first study treatment

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Breast NeoplasmsStudy Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer NCT00372996
  1. La Jolla, California
  2. La Jolla, California
  3. San Diego, California
  4. Washington, District of Columbia
  5. Davie, Florida
  6. Plantation, Florida
  7. Lexington, Kentucky
  8. Lexington, Kentucky
  9. Lexington, Kentucky
  10. Boston, Massachusetts
  11. Boston, Massachusetts
  12. Boston, Massachusetts
  13. Boston, Massachusetts
  14. Boston, Massachusetts
  15. Boston, Massachusetts
  16. Minneapolis, Minnesota
  17. Minneapolis, Minnesota
  18. Minneapolis, Minnesota
  19. Burlington, North Carolina
  20. Durham, North Carolina
  21. Durham, North Carolina
  22. Durham, North Carolina
  23. Durham, North Carolina
  24. Durham, North Carolina
  25. Dallas, Texas
  26. Houston, Texas
  27. Houston, Texas
  28. Burlington, Vermont
  29. Burlington, Vermont
  30. Burlington, Vermont
  31. Burlington, Vermont
  32. Burlington, Vermont
  33. Burlington, Vermont
  34. La Plata, Buenos Aires
  35. La Plata, Buenos Aires
  36. La Plata, Buenos Aires
  37. La Plata, Buenos Aires
  38. Rosario, Santa Fe
  39. Rosario, Santa Fe
  40. Rosario, Santa Fe
  41. Rosario, Santa Fé
  42. Cordoba,
  43. Leuven,
  44. Leuven,
  45. Wilrijk,
  46. Montreal, QC
  47. Santo Cristo, Rio de Janeiro
  48. Porto Alegre, Rio Grande do Sul
  49. Rio de Janeiro, RJ
  50. Porto Alegre, RS
  51. Porto Alegre, RS
  52. Sao Paulo, SP
  53. Porto Alegre,
  54. Rio De Janeiro,
  55. Edmonton, Alberta
  56. Montreal, Quebec
  57. Milano,
  58. Napoli,
  59. Padova,
  60. Amsterdam,
  61. Malmo,
  62. London,
  63. London,
Female
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsA Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer NCT00373256
  1. Bessemer, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Birmingham, Alabama
  6. Birmingham, Alabama
  7. Daphne, Alabama
  8. Mobile, Alabama
  9. Mobile, Alabama
  10. Flagstaff, Arizona
  11. Sedona, Arizona
  12. Hot Springs, Arkansas
  13. Anaheim, California
  14. Antioch, California
  15. Antioch, California
  16. Baldwin Park, California
  17. Bellflower, California
  18. Fontana, California
  19. Fountain Valley, California
  20. Gilroy, California
  21. Hawthorne, California
  22. Hayward, California
  23. Irvine, California
  24. La Jolla, California
  25. Long Beach, California
  26. Los Angeles, California
  27. Los Angeles, California
  28. Los Angeles, California
  29. Martinez, California
  30. Milpitas, California
  31. Modesto, California
  32. Mountain View, California
  33. Oakland, California
  34. Ontario, California
  35. Orange, California
  36. Oxnard, California
  37. Panorama City, California
  38. Pinole, California
  39. Riverside, California
  40. Sacramento, California
  41. San Diego, California
  42. San Diego, California
  43. San Francisco, California
  44. San Francisco, California
  45. San Francisco, California
  46. San Jose, California
  47. San Sacramento, California
  48. Santa Clara, California
  49. Santa Monica, California
  50. Union City, California
  51. Vallejo, California
  52. Walnut Creek, California
  53. Woodland Hills, California
  54. Aurora, Colorado
  55. Boulder, Colorado
  56. Colorado Springs, Colorado
  57. Colorado Springs, Colorado
  58. Denver, Colorado
  59. Denver, Colorado
  60. Lakewood, Colorado
  61. Littleton, Colorado
  62. Lone Tree, Colorado
  63. Longmont, Colorado
  64. Parker, Colorado
  65. Thornton, Colorado
  66. Norwalk, Connecticut
  67. Boca Raton, Florida
  68. Coral Springs, Florida
  69. Davie, Florida
  70. Hollywood, Florida
  71. Inverness, Florida
  72. Lakeland, Florida
  73. Melbourne, Florida
  74. Miami, Florida
  75. Miami, Florida
  76. Miami, Florida
  77. Orlando, Florida
  78. Pembroke Pines, Florida
  79. Tampa, Florida
  80. Winter Park, Florida
  81. Atlanta, Georgia
  82. Atlanta, Georgia
  83. Columbus, Georgia
  84. Columbus, Georgia
  85. Decatur, Georgia
  86. Macon, Georgia
  87. Marietta, Georgia
  88. Chicago, Illinois
  89. Harvey, Illinois
  90. Skokie, Illinois
  91. Tinley Park, Illinois
  92. Vernon Hills, Illinois
  93. Avon, Indiana
  94. Beech Grove, Indiana
  95. Carmel, Indiana
  96. Fishers, Indiana
  97. Greenfield, Indiana
  98. Indianapolis, Indiana
  99. Indianapolis, Indiana
  100. Indianapolis, Indiana
  101. Indianapolis, Indiana
  102. Indianapolis, Indiana
  103. Jeffersonville, Indiana
  104. Mooresville, Indiana
  105. Munster, Indiana
  106. New Albany, Indiana
  107. Kansas City, Kansas
  108. Overland Park, Kansas
  109. Louisville, Kentucky
  110. Louisville, Kentucky
  111. Louisville, Kentucky
  112. Louisville, Kentucky
  113. Louisville, Kentucky
  114. Annapolis, Maryland
  115. Baltimore, Maryland
  116. Baltimore, Maryland
  117. Baltimore, Maryland
  118. Baltimore, Maryland
  119. Columbia, Maryland
  120. Randallstown, Maryland
  121. Burlington, Massachusetts
  122. Peabody, Massachusetts
  123. Coon Rapids, Minnesota
  124. Robbinsdale, Minnesota
  125. Ocean Springs, Mississippi
  126. Pascagoula, Mississippi
  127. Columbia, Missouri
  128. Kansas City, Missouri
  129. Kansas City, Missouri
  130. Kansas City, Missouri
  131. Lee's Summit, Missouri
  132. Fremont, Nebraska
  133. Grand Island, Nebraska
  134. Lincoln, Nebraska
  135. Lincoln, Nebraska
  136. Lincoln, Nebraska
  137. Lincoln, Nebraska
  138. Henderson, Nevada
  139. Henderson, Nevada
  140. Las Vegas, Nevada
  141. Las Vegas, Nevada
  142. Las Vegas, Nevada
  143. Las Vegas, Nevada
  144. Las Vegas, Nevada
  145. Las Vegas, Nevada
  146. Albuquerque, New Mexico
  147. Albuquerque, New Mexico
  148. Buffalo, New York
  149. Corning, New York
  150. Jamaica, New York
  151. Mineola, New York
  152. Cary, North Carolina
  153. Clinton, North Carolina
  154. Durham, North Carolina
  155. Goldsboro, North Carolina
  156. Hickory, North Carolina
  157. Kenansville, North Carolina
  158. Kinston, North Carolina
  159. Lenoir, North Carolina
  160. Pollocksville, North Carolina
  161. Raleight, North Carolina
  162. Raliegh, North Carolina
  163. Richlands, North Carolina
  164. Washington, North Carolina
  165. Wilson, North Carolina
  166. Winston-Salem, North Carolina
  167. Canton, Ohio
  168. Dover, Ohio
  169. Eugene, Oregon
  170. Portland, Oregon
  171. Portland, Oregon
  172. Portland, Oregon
  173. Portland, Oregon
  174. Springfield, Oregon
  175. Tualatin, Oregon
  176. Allentown, Pennsylvania
  177. Bethlehem, Pennsylvania
  178. Ephrata, Pennsylvania
  179. Hershey, Pennsylvania
  180. Kingston, Pennsylvania
  181. Pittsburgh, Pennsylvania
  182. Pittsburgh, Pennsylvania
  183. Sayre, Pennsylvania
  184. Charleston, South Carolina
  185. Easley, South Carolina
  186. Greenville, South Carolina
  187. Greenville, South Carolina
  188. Seneca, South Carolina
  189. Spartanburg, South Carolina
  190. Bristol, Tennessee
  191. Kingsport, Tennessee
  192. Amarillo, Texas
  193. Antonio, Texas
  194. Austin, Texas
  195. Austin, Texas
  196. Austin, Texas
  197. Austin, Texas
  198. Bedford, Texas
  199. Corpus Christi, Texas
  200. Dallas, Texas
  201. Dallas, Texas
  202. Fort Worth, Texas
  203. Fort Worth, Texas
  204. Fort Worth, Texas
  205. Forth Worth, Texas
  206. Houston, Texas
  207. Houston, Texas
  208. Houston, Texas
  209. Kerrville, Texas
  210. Longview, Texas
  211. Midland, Texas
  212. Round Rock, Texas
  213. Round Rock, Texas
  214. Round Rock, Texas
  215. San Antonio, Texas
  216. San Antonio, Texas
  217. San Marcos, Texas
  218. Shenandoah, Texas
  219. Tyler, Texas
  220. Waco, Texas
  221. Ogden, Utah
  222. Arlington, Virginia
  223. Christiansburg, Virginia
  224. Fairfax, Virginia
  225. Leesburg, Virginia
  226. Norton, Virginia
  227. Roanoke, Virginia
  228. Salem, Virginia
  229. Woodbridge, Virginia
  230. Wytheville, Virginia
  231. Federal Way, Washington
  232. Kennewick, Washington
  233. Lakewood, Washington
  234. Moses Lake, Washington
  235. Puyallup, Washington
  236. Tacoma, Washington
  237. Vancouver, Washington
  238. Vancouver, Washington
  239. Wenatchee, Washington
  240. Huntington, West Virginia
  241. Morgantown, West Virginia
  242. Berlin,
  243. Hamburg,
  244. Trier,
  245. Cremona,
  246. Grosseto,
  247. Olbia,
  248. Cabueñes, Gijon
  249. Guadalajara,
  250. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsA Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer NCT00435409
  1. Downey, California
  2. Fresno, California
  3. Montebello, California
  4. Whittier, California
  5. Boca Raton, Florida
  6. Boynton Beach, Florida
  7. Coral Springs, Florida
  8. Hollywood, Florida
  9. Lake Worth, Florida
  10. Lakeland, Florida
  11. Miami, Florida
  12. Miami, Florida
  13. Miami, Florida
  14. Pembroke Pines, Florida
  15. Duluth, Georgia
  16. Lawrenceville, Georgia
  17. Snellville, Georgia
  18. Avon, Indiana
  19. Indianapolis, Indiana
  20. Mooresville, Indiana
  21. Covington, Louisiana
  22. Gretna, Louisiana
  23. Marrero, Louisiana
  24. Metairie, Louisiana
  25. Metairie, Louisiana
  26. New Orleans, Louisiana
  27. Shreveport, Louisiana
  28. Kensington, Maryland
  29. Rockville, Maryland
  30. Corinth, Mississippi
  31. Columbia, Missouri
  32. Billings, Montana
  33. Albuquerque, New Mexico
  34. Albuquerque, New Mexico
  35. Charlotte, North Carolina
  36. Charlotte, North Carolina
  37. Charlotte, North Carolina
  38. Charlotte, North Carolina
  39. Charlotte, North Carolina
  40. Norman, Oklahoma
  41. Oklahoma City, Oklahoma
  42. Tulsa, Oklahoma
  43. Tulsa, Oklahoma
  44. Tulsa, Oklahoma
  45. Clairton, Pennsylvania
  46. Greensburg, Pennsylvania
  47. Pittsburgh, Pennsylvania
  48. Pittsburgh, Pennsylvania
  49. Pottstown, Pennsylvania
  50. Wexford, Pennsylvania
  51. Franklin, Tennessee
  52. Gallatin, Tennessee
  53. Hermitage, Tennessee
  54. Lebanon, Tennessee
  55. Memphis, Tennessee
  56. Murfreesboro, Tennessee
  57. Nashville, Tennessee
  58. Nashville, Tennessee
  59. Nashville, Tennessee
  60. Nashville, Tennessee
  61. Smyrna, Tennessee
  62. Austin, Texas
  63. Austin, Texas
  64. Austin, Texas
  65. Austin, Texas
  66. Beaumont, Texas
  67. Corpus Christi, Texas
  68. Corpus Christi, Texas
  69. Georgetown, Texas
  70. Bountiful, Utah
  71. Layton, Utah
  72. Murray, Utah
  73. Salt Lake City, Utah
  74. Salt Lake City, Utah
  75. West Provo, Utah
  76. West Valley City, Utah
  77. Richmond, Virginia
  78. Richmond, Virginia
  79. Kennewick, Washington
  80. Linz,
  81. Salzburg,
  82. Wels,
  83. Leuven,
  84. Liege,
  85. Namur,
  86. Turnhout,
  87. Yvoir,
  88. Calgary, Alberta
  89. Calgary, Alberta
  90. Oshawa, Ontario
  91. Montreal, Quebec
  92. Montreal, Quebec
  93. Montreal, Quebec
  94. Montreal, Quebec
  95. Montreal, Quebec
  96. Praha 4,
  97. Praha 5,
  98. Praha 5,
  99. Aalborg,
  100. Koebenhavn OE,
  101. Odense,
  102. Montpellier, Cedex 05
  103. Angers cedex 01,
  104. BORDEAUX Cedex,
  105. CAEN Cedex 5,
  106. Lyon,
  107. Nancy,
  108. Paris,
  109. Erlangen,
  110. Frankenthal,
  111. Frankfurt am Main,
  112. Fuerstenwalde,
  113. Goettingen,
  114. Muenster,
  115. Nuernberg,
  116. Stendal,
  117. Ulm,
  118. Voelklingen,
  119. Heraklion, Crete
  120. Athens,
  121. Ioannina,
  122. Patras,
  123. Thessaloniki,
  124. Dublin,
  125. Dublin,
  126. Dublin,
  127. Bologna,
  128. Brescia,
  129. Messina,
  130. Milano,
  131. Palermo,
  132. Parma,
  133. Roma,
  134. Roma,
  135. Saronno (VA),
  136. Torino,
  137. Amsterdam,
  138. Sittard-geleen,
  139. Zwolle,
  140. Levanger,
  141. Oslo,
  142. Lodz,
  143. Lublin,
  144. Warszawa,
  145. Warszawa,
  146. Cluj-Napoca, Cluj
  147. Bucuresti, Sector 2
  148. Kuzmolovo, Vsevolozhsk district, Leningrad region
  149. Moscow,
  150. St. Petersburg,
  151. St. Petersburg,
  152. Barcelona,
  153. Burgos,
  154. Cadiz,
  155. La Coruña,
  156. Madrid,
  157. Madrid,
  158. Sevilla,
  159. Truro, Cornwall
  160. Chelmsford, Essex
  161. Harlow, Essex
  162. Burton upon Trent, Staffordshire
  163. Worthing, West Sussex
  164. Birmingham,
  165. Essex,
  166. London,
  167. Swansea,
  168. Truro,
  169. Worthing,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsExemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer NCT00279448
  1. Marseille, Be1 01971
  2. Compiegne, Be1 02256
  3. Rennes, Be1 03677
  4. Brest, Be1 04292
  5. Aix en Provence,
  6. Amiens,
  7. Annecy Cedex,
  8. Avignon Cedex 2,
  9. Bayonne,
  10. Blois,
  11. Bordeaux CEDEX,
  12. Bordeaux,
  13. Brest,
  14. Cagne sur Mer,
  15. Chalon sur Saone,
  16. Chaumont,
  17. Croix,
  18. Dijon,
  19. Douai,
  20. Draguignan,
  21. Dunkerque,
  22. Evreux,
  23. Hyres,
  24. L'Union,
  25. Le Havre,
  26. Lille,
  27. Lorient,
  28. Lyon,
  29. Mareuil les Meaux,
  30. Marseille,
  31. Marseille,
  32. Marseille,
  33. Metz,
  34. Montauban,
  35. Montbeliard,
  36. Montelimar,
  37. Montpellier,
  38. Mougins,
  39. Nancy,
  40. Nantes Cedex 2,
  41. Neuilly,
  42. NICE Cedex 1,
  43. Nimes,
  44. Paris,
  45. Pessac,
  46. Quincy sous Senart,
  47. Reims,
  48. Ris Orangis,
  49. Saint Brieuc,
  50. Saint Nazaire,
  51. St Cloud,
  52. St Herblain,
  53. Strasbourg,
  54. Toulon,
  55. Toulouse,
  56. Toulouse,
  57. Vandoeuvre les Nancy,
  58. Vannes,
  59. Vannes,
Female
50 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
Official Title  ICMJE Phase 1/2 Open-Label Trial Of Sutent (Sunitinib Malate) And Aromasin(Exemestane) In The First-Line Treatment Of Hormone Receptor-Positive Metastatic Breast Cancer
Brief Summary To assess progression-free survival at the combination dose determined in the Phase 1 portion of the study, and safety of sunitinib combined with exemestane in patients with metastatic or locally-recurrent, unresectable breast cancer.
Detailed Description The trial was terminated prematurely on August 28, 2008 due to the inability to recruit the planned number of subjects in order to provide meaningful efficacy data. There were no safety concerns regarding the study in the decision to terminate the trial.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Neoplasms
Intervention  ICMJE
  • Drug: exemestane
    25 mg, oral, daily dosing
  • Drug: sunitinib malate
    37.5 mg, oral, continuous dosing, daily
    Other Name: sutent
Study Arms  ICMJE Experimental: A
sunitinib + exemestane
Interventions:
  • Drug: exemestane
  • Drug: sunitinib malate
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 18, 2008)		6
Original Enrollment  ICMJE
 (submitted: January 2, 2007)		72
Actual Study Completion Date  ICMJE July 2009
Actual Primary Completion Date July 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • At least 18 years of age
  • Estrogen and/or progesterone receptor positive adenocarcinoma of the breast with evidence of 1) unresectable 2)locally recurrent, or 3) metastatic disease
  • Postmenopausal
  • ECOG [Eastern Cooperative Oncology Group] </=1
  • Evaluable(e.g bone only disease allowed) and Measurable disease [RECIST (Response Evaluation Criterion in Solid Tumors)]

Exclusion Criteria:

  • HER2 [Human Epidermal Growth factor Receptor 2] positive disease not previously treated with herceptin
  • Any prior anti-angiogenic therapy, endocrine or cytotoxic anti-cancer therapy in the metastatic disease setting
  • Radiation therapy within 2 weeks of first study treatment
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00417885
Other Study ID Numbers  ICMJE A6181108
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP